1xbet 온라인., Ltd.

1xbet 온라인., Ltd. announces the granting of approval in Japan for the additional dosage form of Samsca^®granules 1% (tolvaptan), a vasopressin V₂-receptor antagonist.

Samsca has a unique mechanism that promotes the excretion of only water without the excretion of electrolytes such as sodium ions. 1xbet 온라인, it was approved in October 2010 for the treatment of excess water retention in patients with cardiac failure, and in September 2013 for excess water retention for patients with hepatic cirrhosis. In March 2014, it was approved 1xbet 온라인 as the first treatment in the world to slow the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Tolvaptan has been approved since 2009 in the US and Europe 1xbet 온라인 the treatment of hyponatremia. Since 2015, it has been approved 1xbet 온라인 the treatment of ADPKD in Europe, Canada, and South Korea. Currently Samsca/JINARC* is approved 1xbet 온라인 different indications in over 40 countries.
_{*Marketed as JINARC 1xbet 온라인 the treatment of ADPKD outside Japan}